Aims/hypothesis We determined whether oxidative damage in collagen is increased in (1) patients with diabetes; (2) patients with diabetic complications; and (3) subjects from the Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) study, with comparison of subjects from the former standard vs intensive treatment groups 4 years after DCCT completion. Subjects, materials and methods We quantified the early glycation product fructose-lysine, the two AGEs N ɛ -(carboxymethyl)lysine (CML) and pentosidine, and the oxidised amino acid methionine sulphoxide (MetSO) in skin collagen from 96 patients with type 1 diabetes (taken from three groups: DCCT/EDIC patients and clinic patients from South Carolina and Scotland) and from 78 healthy subjects. Results Fructose-lysine was increased in diabetic patients (p<0.0001), both with or without complications (p<0.0001).
Introduction
Modifications of proteins and other macromolecules by glycation, oxidation and 'carbonyl stress' are implicated in the vascular complications of diabetes [1] . In these reactions, the initial glycation product fructose-lysine (FL) is subject to dehydration and rearrangement, forming AGEs such as N ɛ -(carboxymethyl)lysine (CML) and pentosidine [2] . Much AGE formation, especially in extracellular proteins such as skin collagen, is mediated by reactive carbonyl intermediates involving free radical oxidation [1] . Some end-products, e.g. CML, can be derived from either carbohydrates or lipids [3] , and can also form non-oxidatively [4] .
The levels of these end-products in a protein depend on the rate of protein turnover (which itself may be influenced by AGE formation), ambient oxidative stress (i.e. the balance between free radicals and antioxidant defences) and ambient substrate (carbohydrate or lipid) levels. Particularly in long-lived structural proteins such as collagen, it may be difficult to estimate the contribution of these variables to the accumulation of AGEs. Levels of FL in collagen are in equilibrium with ambient glucose [5] , but AGEs accumulate steadily with age, and at an accelerated rate in diabetes [6] . Previous studies found that agecorrected skin collagen concentrations of pentosidine and CML, and Maillard-type fluorescence correlated with the severity of microvascular complications in type 1 diabetes [6] [7] [8] [9] . However, after normalising for diabetes duration and mean glycaemia, AGE levels were actually lower than expected in diabetes [6] . This suggested that elevated AGEs could be accounted for solely by hyperglycaemia, making it unnecessary to invoke any diabetes-associated increase in free radical oxidation. Nevertheless, in a small sub-analysis, diabetic patients with complications tended to have higher adjusted AGE levels than predicted considering glycaemia, whereas those without complications had lower levels [10] . We hypothesised that these differences might be the result of inter-individual variations in oxidative stress modulating susceptibility to complications. According to this hypothesis, people who experience high oxidative stress will be more susceptible to vascular complications, if they become diabetic.
Methionine sulphoxide (MetSO), a direct oxidation product of methionine, provides a means to assess oxidative stress independent of other chemical modifications [11] . Whereas CML and pentosidine require correction for glycaemia over time to be used as indices of oxidative stress, MetSO, a direct oxidation product, does not. Like AGEs, it accumulates in skin collagen with age, but unlike them, according to a small previous study [12] , it is not increased in collagen from diabetic subjects compared to non-diabetic subjects. This again suggested that oxidative stress is not increased, at least in the extracellular compartment, in diabetes. However, that study was too small to test the hypothesis that oxidative stress is higher in complication-prone than in complicationresistant diabetic subjects.
In the present study, we measured FL, CML, pentosidine and MetSO in skin collagen from three groups of complication-prone and complication-resistant type 1 diabetic subjects, and from non-diabetic control subjects. Our goal was to define whether oxidative stress experienced by this extracellular protein is increased in (1) diabetic vs control subjects, (2) diabetic subjects with vs without complications, and (3) standard vs intensive management DCCT/EDIC groups 4 years after DCCT closure.
Subjects, materials and methods

Human subjects
Skin biopsies were provided by 96 subjects with type 1 diabetes and 78 non-diabetic control subjects. The diabetic patients came from three separate groups. The largest group (n=54) was from the DCCT/EDIC cohort [13] . The original DCCT cohort consisted of 1,441 patients aged 13-40 years with 1-15 years of type 1 diabetes at study entry (1983) (1984) (1985) (1986) (1987) (1988) (1989) . Subjects were randomly assigned to standard (STD, n=730) or intensive (INT, n=711) treatment for an average of 6.5 years [13] . The DCCT was stopped in 1993 because evidence appeared of a powerful beneficial effect of the intensive therapy on microvascular complications, and subjects were invited to join EDIC, a multicentre longitudinal epidemiological investigation [14] .
In 1996, a collaborative project between the Medical University of South Carolina (MUSC) and DCCT/EDIC was implemented to identify markers and mechanisms for cardiovascular disease (CVD) in type 1 diabetes. A substudy using skin biopsies to address the role of oxidative stress in complications was implemented at two DCCT/ EDIC centres, Charleston, SC, and Pittsburgh, PA, USA. Of the 54 subjects biopsied in 1997-1999, 26 were from the former INT group and 28 from the STD group.
To increase the study power and relevance, two additional groups of type 1 diabetic subjects were recruited from the diabetes clinics of MUSC (SC Db) and the Western General Hospital, Edinburgh, UK (UK Db). Apparently healthy non-diabetic control subjects were also recruited at these locations (SC Non-Db and UK Non-Db). The age range of the non-diabetic controls was deliberately broader than that of the diabetic groups to define normal rates of end-product accumulation in skin collagen. The 78 control subjects had no history of diabetes, renal failure or known vascular disease. All studies were approved by the Institutional Review Boards at each centre, and each subject gave written informed consent.
Assessment of complications
Diabetic subjects were categorised as 'complicated' or 'noncomplicated' based on a review of their medical records before the skin biopsy. 'Complicated' patients had one or more of the following conditions: pre-proliferative or proliferative retinopathy as defined by an Early Treatment Diabetic Retinopathy Study (ETDRS) score ≥10 by previously described DCCT/EDIC methods of retinal photograph analysis [15] ; microalbuminuria (≥40 mg/24 h, confirmed on at least two occasions) or heavier proteinuria; or a defined macrovascular event (stroke; myocardial infarction, coronary artery by-pass or angioplasty; intermittent claudication or amputation). 'Non-complicated' patients had minimal retinopathy (ETDRS scores ≤3), no proteinuria, and no history of macrovascular events, despite at least 10 years of type 1 diabetes. For the purposes of discussion, the 'complicated' and 'uncomplicated' groups are referred to as being 'complication-prone' and 'complication-resistant'.
Clinical laboratory measures
For DCCT/EDIC subjects, clinical measures were performed as previously described [16] or were obtained from the DCCT/EDIC database. For non-DCCT/EDIC subjects, HbA 1c (by HPLC), plasma and urine analyses were carried out in the clinical laboratories of the respective institutional hospital.
Skin biopsy and collagen preparation
Full-thickness elliptical biopsies (∼0.5×1 cm) were taken from the medial aspect of the buttock (under 2% lidocaine local anaesthesia), rinsed in PBS and immediately frozen (−70°C) until collagen extraction was performed as described elsewhere [17] . Briefly, skin was scraped free of adventitious tissue using a scalpel blade and the remaining extracellular protein matrix was extracted sequentially with 1 mol/l NaCl, 0.5 mol/l acetic acid, and chloroform:methanol (2:1). Each extraction was carried out with gentle mixing (24 h, 4°C). After the final extraction, the insoluble collagen was lyophilised and stored at −70°C until analysed.
Measurement of FL, AGEs and MetSO
Limitations to the biopsy size precluded making all measurements on all samples, but AGEs and MetSO were measured in ≥90% of subjects in each group. FL and CML were quantified by isotope dilution gas chromatography/mass spectrometry using selected ion monitoring (SIM-GC/MS), and pentosidine was quantified by RP-HPLC, as previously described [18] . The concentration of each was normalised to that of the parent amino acid, lysine. Because MetSO is converted to Met during hydrolysis in HCl, MetSO and Met (and d 4 -MetSO, d 4 -Met) were measured separately in 0.5-1 mg protein following hydrolysis (4 h, 150°C) in methanesulphonic acid. The acid was removed by ion exchange chromatography, and the remaining amino acids were derivatised with bis-trimethylsilylacetamide for analysis by SIM-GC/MS [19] . MetSO was expressed as a percentage of total Met, i.e. %MetSO=MetSO/(Met+MetSO).
Data analysis
For simple comparisons of means and proportions between groups, two-tailed t-tests for continuous measures and χ 2 analysis for discrete measures were used. The primary dependent variables (FL, CML, pentosidine and MetSO) were analysed using general linear models. The distributions of the residuals from the full model (all terms included) were tested for approximate normality using the Shapiro-Wilks test. Where necessary (MetSO and pentosidine), the dependent variables were log-transformed before analysis. For all analyses, diabetic patients with and without complications were analysed as separate groups. The primary hypothesis was that the rate of increase in the dependent variables with age was higher in the diabetic patients with complications than in either those without complications or the non-diabetic controls. This was tested in the general linear model by comparing models with an age effect with those where the age effect was nested within each group, that is, fitting a separate age regression within each group. Independent variables included in the models were age, sex, duration of diabetes and HbA 1c levels (except for MetSO). FL was included in models for CML and pentosidine but was found to be equivalent to HbA 1c in effect and was removed. Sex and duration were found to have no significant effect and were dropped from the models. The descriptive statistics in the tables are presented as means±SD. Values of p<0.05 were considered significant. Statistical analyses were performed in SAS (v8) (SAS Institute, Cary, NC, USA). Table 1 describes the clinical characteristics of the subjects in this study. Age did not differ significantly between groups. Both diabetes duration and the percentage of smokers were similar between the two DCCT/EDIC groups, and between the SC and UK Db groups, but each of the latter had a longer duration (p<0.01) and a higher proportion of smokers (p<0.01) than the DCCT/EDIC groups. Approximately 25% of subjects in the previous DCCT INT and UK Db groups had one or more complications, while the fraction of patients with complications was higher (43%) in the DCCT STD group and was highest (67%) in the SC Db group. Plasma lipid levels measured at biopsy were comparable among all diabetic and non-diabetic groups.
Results
Clinical characteristics
Glycaemic control was assessed by both long-term (except SC Db) and short-term HbA 1c data. Long-term HbA 1c levels in the DCCT/EDIC subjects were significantly lower (p<0.001) for patients in the INT vs STD group during the DCCT (1984-1993), but became similar (p>0.05) after 1994 [14] . For the UK Db patients, long-term 'cumulative' HbA 1c was the mean of values obtained at least 3 months apart during the 5 years before the skin biopsy, and in the DCCT/EDIC groups the long-term 'cumulative' HbA 1c level was similar to the recent HbA 1c levels. Recent HbA 1c was therefore used to control the AGE levels for glycaemia. The mean HbA 1c at biopsy was not significantly different among the diabetic groups (not considering complications), and was within the normal range in the two non-diabetic groups. Table 2 summarises the characteristics of the diabetic cohorts according to complication status. Subject age was Table 2 a AGE-modifying drugs include angiotensin-converting enzyme inhibitors, calcium-channel blockers, high-dose vitamin C and/or E, and statins lower (p<0.05) in the patients with complications than in those without complications in the DCCT INT group, but was similar between those with and without complications in the other three groups. Diabetes duration, percentage of smokers and plasma lipids were not statistically different between patients with and without complications in all groups. For all diabetic subjects, HbA 1c at biopsy was higher in patients with complications than in those without (p=0.005). Proliferative retinopathy was the most common complication, followed by microalbuminuria.
The proportion of study subjects from each group taking drugs with antioxidant/AGE-modifying potential (angiotensin-converting enzyme inhibitors, calcium-channel blockers, high-dose vitamin C and/or E, and HMGCoA reductase inhibitors [statins]) at the time of biopsy is shown in Tables 1 and 2 . Overall, 61% of the DCCT group, 29% of the combined SC and UK diabetic subjects and 6% of the control subjects were taking potentially AGE-modifying drugs. Considering all the diabetic subjects together, AGE-modifying drugs were taken by 44% patients with complications and by 46% without complications (not significant, see Table 2 for further details).
FL levels in skin collagen Figure 1 demonstrates both the modest rise in collagen glycation with age in non-diabetic individuals and the marked increase, independent of age or complication status, in diabetic subjects. The mean FL in diabetic subjects was 2.3-fold higher than that of the non-diabetic controls (13.5±3.5 vs 5.9±1.1 mmol/mol lysine, p<0.0001). The increase of FL among diabetic subjects was little affected by adjustment for age, and was similar to the 1.9-fold increase in mean blood glucose estimated from HbA 1c values [20] .
Mean FL values were higher in diabetic patients with complications than in those without complications (15.3± 3.7 vs 12.5±3.0 mmol/mol lysine, p=0.0002). This difference also reached statistical significance for patients with and without complications in the DCCT INT group (p<0.05), and for the combined DCCT INT+STD group (p<0.001). Comparing the DCCT INT and STD groups, there was no significant difference in collagen glycation (FL 13.6±3.6 vs 14.0±4.2 mmol/mol lysine), consistent with their similar HbA 1c levels both during EDIC and at biopsy (Table 1) . CML and pentosidine levels in collagen were strongly related to age in both diabetic and non-diabetic populations (Fig. 2) , and age-corrected concentrations were significantly higher both in groups of diabetic vs non-diabetic individuals (p<0.001), and in groups of diabetics with vs without complications (CML: p=0.035; pentosidine: p=0.003). Controlling for HbA 1c to estimate oxidative stress, rates of accumulation of CML and pentosidine (the latter with or without log-transformation to normalise data) with age were higher in diabetic patients with complications than in non-diabetic controls (p<0.0001). For CML only, the rate of accumulation was also higher in diabetic patients without complications than in controls (p<0.0001). Importantly, the rates of accumulation of both AGE products, controlling for HbA 1c , were higher in diabetic patients with complications than in those without (p<0.0001). Use of collagen FL to control for glycaemia instead of HbA 1c yielded the same conclusion. Although AGE products provide only an indirect estimate of oxidative stress, one that requires correction for glycaemia, the data support an increase in the rate of oxidative damage to collagen in diabetic subjects with complications compared with those without complications. The CML data suggested an increase even in patients who do not have complications. These effects were observed despite a higher intake of anti-oxidant, potentially AGE-modifying, drugs in both groups of diabetic subjects. No differences in agecorrected CML and pentosidine were found between the DCCT INT and STD groups, even after correction for HbA 1c , nor did the rates of accumulation with age differ after accounting for HbA 1c .
Collagen MetSO and diabetic complications
The measurement of MetSO in collagen provides a direct measure of oxidative damage in diabetes. As shown in Fig. 3 , MetSO accumulated with age in both diabetic subjects and non-diabetic controls. The rate of accumulation was significantly increased in diabetic patients with complications compared with either those without complications or non-diabetic controls (both p<0.0001). Rates for diabetic patients without complications and control subjects were similar. These results support the presence of increased oxidative stress over time in diabetic patients with complications, but not in those without. MetSO levels did not differ significantly between DCCT INT and STD after controlling for age.
Discussion
Our goal was to determine associations between oxidative modification of skin collagen and the presence of type 1 diabetes and/or its complications. In diabetes, levels of glycation and AGE products are increased in long-lived proteins such as collagen [5, 6] . Since AGE formation involves free radical oxidation as well as glycation, AGE levels may be used to assess cumulative oxidative stress if corrected for long-term glycaemia. In this study, two AGE products, CML and pentosidine, were measured. A more direct measure of cumulative oxidative damage to collagen, MetSO, provides an alternative index of oxidative damage and obviates the need to control for long-term glycaemia. The diabetic subjects in this study were from the DCCT/ EDIC cohort and clinics in South Carolina and Scotland. The use of these diverse diabetic groups should make our data more generally applicable, with the greatest difference in lifetime diabetes experience likely to be between the former DCCT INT group and all others. For all three products measured, the data strongly support an increased rate of oxidative damage to skin collagen in complicationprone vs complication-resistant diabetic subjects. In the case of CML, but not pentosidine or MetSO, there was evidence of an increased rate of oxidative damage in Fig. 2 Age-dependence of AGEs in skin collagen in diabetic and non-diabetic individuals. CML (a) was measured by SIM-GC/MS and pentosidine (b) by reversed-phase HPLC in skin collagen from non-diabetic controls (+, n=78), diabetic patients with complications (■, n=35) and diabetic patients without complications (□, n=59). The size of the symbol increases with duration of diabetes. AGE accumulation in skin collagen was strongly related to age in both diabetic and non-diabetic populations as shown by the regression lines (---non-diabetic, -diabetic with complications, ⋯ diabetic without complications). Agecorrected levels of both AGEs were significantly higher in both groups of diabetic vs non-diabetic individuals and in diabetic patients with vs those without complications. Controlling for HbA 1c , rates of accumulation of AGEs were higher in diabetic patients, whether with complications (CML and pentosidine (log e [pentosidine])) or without (CML only) (all p<0.0001), than in controls. For both products, rates of accumulation with age were significantly higher in diabetic patients with complications than in those without (all p<0.0001) diabetic patients without complications vs non-diabetic control subjects. It should be noted that consumption of potentially anti-oxidant medications was higher in both complication-prone and complication-resistant diabetic groups (though similar between them) than in the nondiabetic group, potentially disguising a greater effect of diabetes. Four years after completion of the DCCT, during which time there had been similar glycaemic control in the former INT and STD groups, there were no significant differences in AGEs or MetSO.
Collagen glycation, glycaemic control and complications
In this study, FL was increased twofold in diabetic vs control subjects, a finding which was congruent, after correction for differences in glycaemia, with the threefold increase in FL found in type 1 diabetic subjects in our earlier study [6] . The data support the assumption that the formation of collagen FL is in equilibrium with ambient glucose concentrations [5] . Glycation alone may have a pathogenic role in the development of diabetic complications, and collagen FL is a predictor of complications in DCCT subjects [21, 22] .
Monnier et al. [21] , in a separate cohort of DCCT/EDIC subjects, reported a significant difference in collagen FL (furosine) between patients from the INT and STD groups. However, that difference was no longer observed in our study, in which biopsies were performed 4 years later. This is consistent with the convergence of HbA 1c values in the two DCCT randomisation groups through the first 4 years of the EDIC study [14] . Although collagen glycation is believed to provide a longer term estimate of glycaemia than HbA 1c , the exact duration to which it relates is unclear. Further, both collagen FL and HbA 1c may reflect longer term glycaemia than theoretically expected, simply because many patients maintain the same degree of glycaemic control for more prolonged periods. It has been suggested that collagen glycation may directly reflect cumulative glycaemia for at least 1 year before measurement [21] . However, our earlier study of type 1 diabetic patients showed that 4 months of intensive therapy decreased skin collagen FL by 25%, while having no effect on levels of collagen AGEs [5] .
AGEs, MetSO and complications
Collagen AGE content increased with age in all groups, and at an accelerated rate in diabetes, confirming earlier studies with both skin collagen and lens proteins [6, 23, 24] . Controlling for age, the mean concentrations of CML and pentosidine were significantly higher in diabetic individuals than in non-diabetics, and in diabetic groups with complications than in those without. This finding was expected, and is consistent with the association of hyperglycaemia with complication status. Controlling for (estimated longterm) glycaemia, using HbA 1c (or collagen FL, data not shown), the rates of CML and pentosidine accumulation were significantly greater in complication-prone than complication-resistant subjects, suggesting increased oxidative stress in the complication-prone group. This finding was supported by similar findings with MetSO, in which no correction for glycaemia is needed. Fig. 3 Age-dependent accumulation of the oxidation product MetSO in skin collagen in diabetic and non-diabetic individuals. MetSO was measured by SIM-GC/MS in non-diabetic subjects (n=55), diabetic patients without complications (n=47), and diabetic patients with complications (n=33). MetSO (log e [MetSO]) accumulated more rapidly in diabetic patients with complications than in controls (p<0.0001), but rates in uncomplicated patients and controls were similar. Key, see Figs. 1 and 2 In contrast, when diabetic patients who were complication-resistant were compared with non-diabetic controls, only CML (and not pentosidine or MetSO) showed evidence of increased oxidative stress. It should be remembered that CML is not only an AGE, but also an 'advanced lipoxidation product' (ALE) [3] , perhaps contributing to this distinct association.
The present findings are broadly consistent with our earlier study [6] , which did not include a group of patients specifically recruited as complication-prone or complication-resistant. In that study, we concluded that increased collagen CML, pentosidine and fluorescence in type 1 diabetes could be explained entirely by the increase in glycation without invoking increased oxidative stress [6] . However, data from the small number of patients with complications in that study suggested that they might represent a subgroup experiencing higher levels of oxidative damage. The present study strongly supports that contention.
Neither raw nor age-corrected CML, pentosidine, or MetSO levels, nor HbA 1c -corrected rates of product accumulation over time, differed significantly between subjects from the two former DCCT/EDIC randomisation groups. Concerning absolute levels, this contrasts with the significant differences in collagen AGE levels between patients from the INT vs the STD group at the end of the DCCT, 4 years earlier [21] . Even in that study, however, rates of accumulation (regression line gradients) appeared broadly similar in the two DCCT randomization groups, as they do in our study. The data support the contention that 4 years is a sufficient period of time for equilibration even of the end-products. Given that the recent DCCT report shows that the skin collagen FL and CML levels measured earlier (in 1991-1992) predict the 10-year incidence of retinopathy and nephropathy during EDIC [22] , the combination of observations adds further support to the idea that damage resulting from glycation and CML formation may have long-term downstream effects that may explain the 'memory effect' of intensive treatment found during the DCCT.
In contrast to AGEs, which are products of mixed glycation and oxidation, MetSO provides an independent assessment of oxidative damage to protein. MetSO also provides much greater sensitivity than AGEs for assessing protein oxidation with age [12] and avoids variations caused by differing levels of deglycating enzyme activity among individuals [25] .
In agreement with our earlier report [12] , the present results showed similar rates of collagen MetSO accumulation with age in complication-resistant diabetic and non-diabetic subjects, but a markedly increased rate in complication-prone patients. This suggests that people who have greater than average accumulation of MetSO with age, and who also develop diabetes, may be more susceptible to complications.
Increased rates of accumulation of AGEs and MetSO in patients with complications may reflect enhanced oxidative stress, impaired antioxidant defences, or both. Indirect evidence suggests that a reduced antioxidant capacity could explain the increased MetSO in patients with complications. MetSO can be reduced back to methionine by MetSO reductase, which uses thioredoxin as a co-factor [26] . It has been reported that hyperglycaemia in diabetic animals inhibits thioredoxin function in aortic smooth muscle cells through induction of thioredoxin-interacting protein, an endogenous inhibitor of thioredoxin, leading to increased oxidative stress [27] . This effect is restorable by silencing of the gene encoding thioredoxin-interacting protein and by insulin treatment. Thioredoxin-interacting protein is also induced by glucose incubation in mesangial cells [28] . Therefore, such an impaired thioredoxin system could render patients particularly vulnerable to environmental perturbations, and could make an important contribution to the development of diabetic complications and the increase in MetSO.
Our results suggest that oxidation could be an independent risk factor for vascular complications in diabetes. It would be of interest to see whether this also applies to vascular disease in non-diabetic patients but this is beyond the scope of the present study.
Many drugs, such as angiotensin-converting enzyme inhibitors, calcium-channel blockers, antioxidant vitamins and statins, have potential 'AGE-modifying' activity that could affect our results and interpretation [29] [30] [31] [32] . Overall, 61% of DCCT/EDIC subjects, 29% of (non-DCCT) South Carolina or Edinburgh diabetic patients and 6% of control subjects were taking at least one of the potentially antioxidant drugs (Table 1) . However, comparing the diabetic patients with and without complications, we found no significant difference in antioxidant consumption within either the DCCT/EDIC group (64 vs 59%) or the combined SC Db and UK Db groups (28 vs 25%). Combining the diabetic groups, we again did not find any difference in consumption of these medications between patients with or without complications (44 vs 46%). Thus, our evidence does not support a difference in antioxidant consumption as an explanation for differences in oxidative damage (MetSO) levels between patients with and without complications, but the medications could have disguised a general effect of diabetes in enhancing oxidative damage.
The limitations of this study include its relatively small sample size and the grouping together of several different complications in defining patient categories. Therefore, caution is needed in interpreting these results, and further confirmatory work is required. Our findings are for skin collagen and do not address the effects of diabetes and its complications on intracellular oxidative stress [33] . Also, the data do not define the potential effects of localised oxidative stress in complication-prone microenvironments, as suggested by increased ortho-and meta-tyrosine in the diabetic retina [34] . Finally, this cross-sectional study cannot reveal whether the increased rates of AGE and MetSO accumulation are a cause or an effect (or neither) of the complications.
In summary, measurement of skin collagen AGEs and MetSO suggests an increased rate of oxidative damage to collagen in diabetic patients who are prone to vascular complications compared to those who are resistant, but little difference (after accounting for glycaemia as appropriate) between patients with uncomplicated diabetes and nondiabetic control subjects. We did not find significant differences in levels of collagen glycation, AGEs or MetSO between previous DCCT INT and STD groups. Our results suggest that skin collagen AGE (corrected for glycaemic control) and MetSO might be used as surrogate markers to identify diabetic patients who are at high risk of complications, as well as an endpoint for monitoring therapeutic effects.
